spark-therapeutics

Spark Therapeutics is a Philadelphia-based gene therapy company founded in 2013 with roots at Children's Hospital of Philadelphia (CHOP). Spark developed Luxturna (voretigene neparvovec-rzyl), the first FDA-approved gene therapy for a genetic disease in the United States, approved in December 2017 for the treatment of inherited retinal disease caused by biallelic RPE65 mutations. Roche acquired Spark Therapeutics in December 2019 for approximately $4.3 billion, and Spark has since been integrated into the Roche Group, operating as a Genentech subsidiary. The original sparktx.com domain now redirects to gene.com/spark. Spark does not publish any public developer APIs, OpenAPI specifications, SDKs, or GitHub organization. As a pharmaceutical/biotech operating under Roche, Spark's public technical surface is limited to patient and prescriber information for Luxturna and adverse event reporting channels (FDA MedWatch and 1-855-SPARKTX).

spark-therapeutics is profiled on the APIs.io network. Tagged areas include Biotechnology, Pharmaceuticals, Gene Therapy, Rare Disease, and Ophthalmology.

🌐 Visit website 📡 Source on GitHub

12.0/100 minimal ▬ flat Agent 0/100 human only Full breakdown ↓
scored 2026-07-27 · rubric v0.5

0 APIs

BiotechnologyPharmaceuticalsGene TherapyRare DiseaseOphthalmologyInherited Retinal DiseaseRoche SubsidiaryLife Sciences

Kin Score

Kin Score How this is scored →
scored 2026-07-27 · rubric v0.5

Composite quality — 12.0/100 · minimal

Contract Quality 0.0 / 25

Developer Ergonomics 0.0 / 20

Commercial Clarity 0.0 / 20

Operational Transparency 0.0 / 13

Governance 1.6 / 12

Discoverability 6.0 / 10

Agent readiness — 0/100 · human only

Machine-Readable Contract 0 / 18

Agentic Access Contract 0 / 15

MCP Server 0 / 12

Machine-Readable Auth 0 / 10

Idempotency 0 / 9

Stable Error Semantics 0 / 8

Request/Response Examples 0 / 7

Rate-Limit Signaling 0 / 7

Typed Event Surface 0 / 6

Agent Skills 0 / 5

Well-Known Catalog 0 / 4

Consent & Bot Identity 0 / 3

Improve this rating by publishing the missing artifacts — every area above can be raised, and the full rubric is at apis.io/rating/. This rating is computed from github.com/api-evangelist/spark-therapeutics: open an issue to ask a question, or submit a pull request to add artifacts. Want it done for you? Prioritized profiling — $2,500 →

Get Started 1

Portal, sign-up, and the first successful call

PatientPortal

PatientPortal

Design & Contract 1

Pagination, idempotency, versioning, errors, and events

Vocabulary

Vocabulary

Access & Security 2

Authentication, authorization, and security posture

VulnerabilityDisclosure

VulnerabilityDisclosure

DomainSecurity

DomainSecurity

Company 2

The organization behind the API

Website

Website

LinkedIn

Other 4

Properties that don't map to a standard resource type

ProductInformation

ParentCompany

ParentCompany

Wikipedia

Source (apis.yml)

aid: spark-therapeutics
accessModel:
  pricing: unknown
  onboarding: unknown
  trial: false
  try_now: false
  public: false
  label: Unknown
  confidence: low
  source: []
  generated: '2026-07-22'
  method: derived
image: https://kinlane-images.s3.amazonaws.com/shared/apis-json/icons/spark-therapeutics.png
url: https://raw.githubusercontent.com/api-evangelist/spark-therapeutics/refs/heads/main/apis.yml
modified: '2026-05-23'
description: Spark Therapeutics is a Philadelphia-based gene therapy company founded in 2013 with roots at Children's Hospital
  of Philadelphia (CHOP). Spark developed Luxturna (voretigene neparvovec-rzyl), the first FDA-approved gene therapy for a
  genetic disease in the United States, approved in December 2017 for the treatment of inherited retinal disease caused by
  biallelic RPE65 mutations. Roche acquired Spark Therapeutics in December 2019 for approximately $4.3 billion, and Spark
  has since been integrated into the Roche Group, operating as a Genentech subsidiary. The original sparktx.com domain now
  redirects to gene.com/spark. Spark does not publish any public developer APIs, OpenAPI specifications, SDKs, or GitHub organization.
  As a pharmaceutical/biotech operating under Roche, Spark's public technical surface is limited to patient and prescriber
  information for Luxturna and adverse event reporting channels (FDA MedWatch and 1-855-SPARKTX).
apis: []
common:
- type: VulnerabilityDisclosure
  url: security/spark-therapeutics-vulnerability-disclosure.yml
- type: DomainSecurity
  url: security/spark-therapeutics-domain-security.yml
- type: Website
  url: https://www.gene.com/spark
- type: ProductInformation
  url: https://luxturna.com
- type: PatientPortal
  url: https://mysparkgeneration.com
- type: ParentCompany
  url: https://www.roche.com
- type: ParentCompany
  url: https://www.gene.com
- type: LinkedIn
  url: https://www.linkedin.com/company/spark-therapeutics
- type: Wikipedia
  url: https://en.wikipedia.org/wiki/Spark_Therapeutics
- type: Vocabulary
  url: https://raw.githubusercontent.com/api-evangelist/spark-therapeutics/refs/heads/main/vocabulary/spark-therapeutics-vocabulary.yml
tags:
- Biotechnology
- Pharmaceuticals
- Gene Therapy
- Rare Disease
- Ophthalmology
- Inherited Retinal Disease
- Roche Subsidiary
- Life Sciences

spark-therapeutics

Kin Score

Security Posture 2

Spark Therapeutics Domain Security

Spark Therapeutics Vulnerability Disclosure

Resources